Head of Research, Krungthai XSpring

Waraporn Wiboonkanarak

Head of Research

A full service Thai brokerage

Krungthai XSpring

Krungthai XSpring is a full service broker. The company provides a wide range of investment services such as Securities Brokerage, Derivative Agent Business, Securities Borrowing and Lending, Securities Trading, Underwriting, Financial Advisory, Wealth Advisory, Private Fund Management and International Markets Securities Trading. 

In terms of credibility, Fitch Ratings has assigned Krunghtai XSpring a long-term rating of AA- and a national short-term rating of F1+ with stable outlook.

Equity Bottom-Up

Samart Aviation Solutions Public Co Ltd / Equity Bottom-Up

Samart Aviation Solutions Public Co Ltd (SAV TB)

<ul><li>Technically, the SET Index is expected to weaken, with the support levels at 1,236/1,230 points and resistance at 1,254/1,260 points.</li><li>In the medium term, the index remains in a zig-zag down downtrend, searching for a bottom within the range of 1,220-1,506 points.</li><li>In the short term, the first signs of a pullback have emerged after the index formed a lower high and lower low pattern for the first time since the technical rebound began on February 17 from the new low of 1,236.80 points.</li></ul>

Technically, the SET Index is expected to weaken, with the support levels at 1,236/1,230 points and resistance at 1,254/1,260 points.In the medium term, the index remains in a zig-zag down downtrend, searching for a bottom within the range of 1,220-1,506 points.In the short term, the first signs of a pullback have emerged after the index formed a lower high and lower low pattern for the first time since the technical rebound began on February 17 from the new low of 1,236.80 points.

Rojana Industrial Park / Equity Bottom-Up

<ul><li>Technically, the SET Index is expected to move sideways, with resistance at 1,270/1,275 points and the support at 1,254/1,244 points.</li><li>In the medium term, the index remains in a zig-zag down downtrend, searching for the bottom within the 1,220-1,506 point range.</li><li>In the short term, a technical rebound is underway after the index hit a 4-year 3-month low at 1,236.80 points (on the morning of Monday, Feb. 17).</li></ul>

Technically, the SET Index is expected to move sideways, with resistance at 1,270/1,275 points and the support at 1,254/1,244 points.In the medium term, the index remains in a zig-zag down downtrend, searching for the bottom within the 1,220-1,506 point range.In the short term, a technical rebound is underway after the index hit a 4-year 3-month low at 1,236.80 points (on the morning of Monday, Feb. 17).

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Laboratory Corporation of America Holdings / Equity Bottom-Up

Laboratory Corporation of America Holdings (LH US)

Laboratory Corporation of America Holdings

<ul><li>Laboratory Corporation of America Holdings (LabCorp) presented a mixed but generally positive financial report in their latest call, providing signals for investors to weigh both an optimistic outlook and some ongoing challenges.</li><li>LabCorp's performance in 2024 was highlighted by a 10% increase in revenue compared to the previous year, totaling $3.3 billion for the fourth quarter alone.</li><li>Their Diagnostics and Biopharma Laboratory Services segments each demonstrated a commendable 10% growth.</li></ul>

Laboratory Corporation of America Holdings (LabCorp) presented a mixed but generally positive financial report in their latest call, providing signals for investors to weigh both an optimistic outlook and some ongoing challenges.LabCorp's performance in 2024 was highlighted by a 10% increase in revenue compared to the previous year, totaling $3.3 billion for the fourth quarter alone.Their Diagnostics and Biopharma Laboratory Services segments each demonstrated a commendable 10% growth.

LH US - Labcorp Holdings: Is Its Stronghold in Diagnostics Under Threat?

<ul><li>Labcorp Holdings has posted its financial results for the third quarter of 2024, reflecting robust growth and operational advancements, although not without its challenges.</li><li>The company reported a revenue increase of 7% year-over-year to $3.3 billion, with Diagnostics Laboratories exhibiting a 9% growth while Biopharma Laboratory Services rose by approximately 3%.</li><li>Despite these growth figures, the company faced margin pressures, partially due to the integration of Invitae, resulting in a 40-basis point decrease in enterprise margins.</li></ul>

Labcorp Holdings has posted its financial results for the third quarter of 2024, reflecting robust growth and operational advancements, although not without its challenges.The company reported a revenue increase of 7% year-over-year to $3.3 billion, with Diagnostics Laboratories exhibiting a 9% growth while Biopharma Laboratory Services rose by approximately 3%.Despite these growth figures, the company faced margin pressures, partially due to the integration of Invitae, resulting in a 40-basis point decrease in enterprise margins.

Laboratory Corporation of America Holdings (LabCorp):  Advancement in Oncology Diagnostics & Other Major Highlights Of Q3 That Could Have A Long Term Impact! - Financial Forecasts

<ul><li>Labcorp Holdings Inc. delivered a robust performance in the second quarter of 2024, showcasing a continued upward trajectory in its business operations.</li><li>The company reported impressive figures with revenues totaling $3.2 billion, reflecting a 6% increase compared to the same period in 2023.</li><li>Adjusted earnings per share (EPS) also saw an appreciable rise, reaching $3.94, signifying a 15% increase.</li></ul>

Labcorp Holdings Inc. delivered a robust performance in the second quarter of 2024, showcasing a continued upward trajectory in its business operations.The company reported impressive figures with revenues totaling $3.2 billion, reflecting a 6% increase compared to the same period in 2023.Adjusted earnings per share (EPS) also saw an appreciable rise, reaching $3.94, signifying a 15% increase.

Laboratory Corporation of America Holdings (LabCorp): Expansion into Hospital & Regional Laboratory Markets & Focus on High-Growth Specialty Testing Markets! - Major Drivers

United States

Laboratory Corporation of America Holdings is a clinical laboratory company that offers clinical laboratory tests used by the medical profession in routine testing, patient diagnosis, and in the monitoring and treatment of disease. The Company develops specialty testing operations, such as oncology testing, HIV genotyping and phenotyping, diagnostic genetics and clinical trials.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Laboratory Corporation of America Holdings (LH US)

Strategic Daily Picks

Technically, the SET Index is expected to weaken, with the support levels at 1,236/1,230 points and resistance at 1,254/1,260 points. In the...

Krungthai XSpring

Strategic Daily Picks

Technically, the SET Index is expected to move sideways, with resistance at 1,270/1,275 points and the support at 1,254/1,244 points. In the...

Krungthai XSpring

LH US - Labcorp Holdings: Is Its Stronghold in Diagnostics Under Threat?

Laboratory Corporation of America Holdings (LabCorp) presented a mixed but generally positive financial report in their latest call, providing...

Baptista Research

Laboratory Corporation of America Holdings (LabCorp): Advancement in Oncology Diagnostics & Other Major Highlights Of Q3 That Could Have A Long Term Impact! - Financial Forecasts

Labcorp Holdings has posted its financial results for the third quarter of 2024, reflecting robust growth and operational advancements, although...

Baptista Research

Laboratory Corporation of America Holdings (LabCorp): Expansion into Hospital & Regional Laboratory Markets & Focus on High-Growth Specialty Testing Markets! - Major Drivers

Labcorp Holdings Inc. delivered a robust performance in the second quarter of 2024, showcasing a continued upward trajectory in its business...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)